Zomedica Pharmaceuticals Corp (ZOM) - Total Liabilities
Based on the latest financial reports, Zomedica Pharmaceuticals Corp (ZOM) has total liabilities worth $10.55 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Zomedica Pharmaceuticals Corp's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Zomedica Pharmaceuticals Corp - Total Liabilities Trend (2012–2024)
This chart illustrates how Zomedica Pharmaceuticals Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ZOM asset base.
Zomedica Pharmaceuticals Corp Competitors by Total Liabilities
The table below lists competitors of Zomedica Pharmaceuticals Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
City Service SE
WAR:CTS
|
Poland | zł66.34 Million |
|
ImmunoPrecise Antibodies Ltd.
NASDAQ:HYFT
|
USA | $8.40 Million |
|
Unifosa
TWO:8277
|
Taiwan | NT$30.92 Million |
|
FLUOGUIDE A/S DK -1
F:96X
|
Germany | €33.76 Million |
|
5E ADVANCED MATLS NEW
F:J9I1
|
Germany | €6.99 Million |
|
Pangaea Oncology S.A.
MC:PANG
|
Spain | €10.05 Million |
|
Donkeyrepublic Holding AS
CO:DONKEY
|
Denmark | Dkr77.40 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Zomedica Pharmaceuticals Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Zomedica Pharmaceuticals Corp (ZOM) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zomedica Pharmaceuticals Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zomedica Pharmaceuticals Corp (2012–2024)
The table below shows the annual total liabilities of Zomedica Pharmaceuticals Corp from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.70 Million | -11.26% |
| 2023-12-31 | $13.18 Million | +7.87% |
| 2022-12-31 | $12.22 Million | +28.42% |
| 2021-12-31 | $9.51 Million | -36.90% |
| 2020-12-31 | $15.08 Million | +622.30% |
| 2019-12-31 | $2.09 Million | -12.16% |
| 2018-12-31 | $2.38 Million | +186.76% |
| 2017-12-31 | $828.74K | +11.82% |
| 2016-12-31 | $741.16K | +406.64% |
| 2015-12-31 | $146.29K | +3620.99% |
| 2014-12-31 | $3.93K | -23.76% |
| 2013-12-31 | $5.16K | +427.95% |
| 2012-12-31 | $976.80 | -- |
About Zomedica Pharmaceuticals Corp
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital sign… Read more